On March 5, 2020 Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx plant cell-based protein expression system, reported that it will release its financial results for fourth quarter and full-year 2019 and business update on Thursday, March 12, 2020 (Press release, Protalix, MAR 5, 2020, View Source [SID1234555250]). The Company’s management will host a conference call to discuss the financial results and provide a business update on recent corporate and clinical developments at 8:30 a.m. Eastern Time (ET).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Call Details:

Thursday, March 12, 2020, 8:30 a.m. Eastern Time (ET)

Domestic:

877-423-9813

International:

201-689-8573

Conference ID:

13699970

Webcast:

Public Link

The conference call will also be broadcast live and available for replay for two weeks on the Company’s website, www.protalix.com, in the Events Calendar of the Investors section. Please access the Company’s website at least 15 minutes ahead of the conference to register, download, and install any necessary audio software.

On March 5, 2020 Biocept, Inc. (NASDAQ: BIOC) ("Biocept" or the "Company"), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, reported that on March 4, 2020 it entered into a securities purchase agreement with several institutional investors for the issuance and sale of 16,000,000 shares of its common stock at a price of $0.41 per share, for aggregate gross proceeds of approximately $6.6 million, in a registered direct offering priced at-the-market under Nasdaq rules (Press release, Biocept, MAR 5, 2020, View Source [SID1234555249]). The Company currently expects that the proceeds from this registered direct offering, along with the approximate $9.2 million in gross proceeds from the Company’s registered direct offering announced on March 2, 2020 and its current cash and cash equivalents, will be sufficient to fund its current operations through at least December 31, 2020.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Maxim Group LLC is acting as the sole placement agent for the offering.

The offering is expected to close on or about March 6, 2020, subject to the satisfaction of customary closing conditions.

The common shares are being offered pursuant to a shelf registration statement on Form S-3 (File No. 333-224946) previously filed and declared effective by the Securities and Exchange Commission (SEC). The offering of the shares of common stock will be made only by means of a prospectus supplement that forms a part of the registration statement.

This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor will there be any sales of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. A prospectus supplement relating to the shares of common stock will be filed by Biocept with the SEC. When available, copies of the prospectus supplement relating to the registered direct offering, together with the accompanying prospectus, can be obtained at the SEC’s website at www.sec.gov or from Maxim Group LLC, 405 Lexington Avenue, New York, NY 10174, Attention: Syndicate Department, or via email at [email protected] or telephone at (212) 895-3745.

On March 5, 2020 COTA, Inc., a healthcare technology company that uses real-world data (RWD) to bring clarity to cancer care, reported its board of directors has appointed C.K. Wang, M.D. as the company’s chief medical officer (CMO) (Press release, COTA, MAR 5, 2020, View Source [SID1234555248]). Since joining COTA in 2018, Dr. Wang has demonstrated his dedication to advancing COTA’s mission of improving cancer care and treatment through his leadership of clinical data abstraction operations. In his new role, Dr. Wang will be leading the medical team to meet the interest and demand for real-world data in cancer care.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Since joining COTA, I’ve been able to collaborate with provider and life science partners as we move closer to our shared vision – that everyone touched by cancer receives a clear path to care," said Dr. Wang. "We’re on the cusp of truly changing how real-world data is applied in cancer care and drug discovery, and I look forward to continuing to drive this industry transformation in my expanded role."

"As COTA enters its next phase of growth, we are proud that our executive leadership team is fully aligned and embodies a steadfast commitment to our mission of bringing clarity to cancer care," said Mike Doyle, President and CEO of COTA. "Dr. Wang’s impact on our organization to date has been truly remarkable. His perspective, developed from over a decade managing cancer practices and establishing new cancer programs, will be a great asset to COTA as we develop new oncology solutions to serve our partners across the industry. We look forward to applying his unique skill set across a broader set of initiatives as we continue to improve cancer care for patients."

Prior to working with COTA, Dr. Wang served as the Acting Deputy Chief Health Officer for Oncology/Genomics and the Global Oncology Leader at IBM Watson Health. Earlier in his career as a medical oncologist, Dr. Wang worked in private practice in the Dallas/Fort Worth area where he held multiple management and leadership positions including managing partner with Dallas Oncology Consultants, P.A., Director of Oncology with Medical Clinics of North Texas, P.A. and Cancer Program Chairman with the USMD Hospital in Arlington. He received his undergraduate training at Washington University in St. Louis and his M.D. from the University of Texas Health Science Center at San Antonio before completing his residency at University Hospitals in Cleveland, OH and his hematology/ oncology fellowship at the University of Texas Southwestern Medical Center.

On March 5, 2020 Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company, reported the advancement of their first-in-human, phase 1 study with the cancer treatment Debio 0123, an oral, potent and highly selective WEE-1 inhibitor, in combination with carboplatin in patients with advanced solid tumors (Press release, Debiopharm, MAR 5, 2020, View Source [SID1234555247]). This dose escalation trial will be conducted in patients with refractory solid tumors that have recurred or progressed following prior platinum-based chemotherapy and for which no standard treatment is available. Currently one of three WEE1 inhibitors in clinical development, the Debio 0123 program was initiated based on the deepened understanding of the DNA damage response (DDR) of cancer cells.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Initially discovered by the cutting edge biotech company, Almac Discovery, before being licensed by Debiopharm, Debio 0123 has shown anti-tumor activity both as a single agent and in combination with carboplatin in pre-clinical cancer models. The advancement of Debio 0123 into clinical studies may reveal improved therapeutic results for cancer patients.

"This clinical phase of Debio 0123 is highly anticipated in light of the therapeutic potential of the molecule. Pre-clinical research results suggest that this potent WEE-1 inhibitor has the potential to show activity in cancer patients, particularly in combination with DNA damaging treatments, such as chemo- and radiation-therapies" explained Angela Zubel, Chief Development Officer, Debiopharm.

The DNA in cancer cells can be damaged by a variety of treatments such as radiation, antimetabolites, alkylating agents, DNA topoisomerase inhibitors and platinum-based chemotherapy. When this damage occurs, the cells respond by pausing the cell cycle temporarily to allow for DNA repair, hence reducing the effectiveness of cytotoxic therapies against the cancer cells. Treatments such as Debio 0123 which inhibit the DDR are promising drug candidates as they can enhance the effects of DNA damaging therapies and promote a lethal response. The WEE-1 kinase is a key regulator of several cell cycle checkpoints including G2/M. WEE-1 inhibition can force cells in a state of arrest to continue the cell cycle, ultimately leading to cell death. The resulting impairment of the G2-M checkpoint would prevent cancer cells from repairing induced DNA damage, considerably enhancing the effect of the DNA damaging therapy and thus optimizing the therapeutic outcome.

Debiopharm’s commitment to patients
Debiopharm develops innovative therapies that target high unmet medical needs in oncology and bacterial infections. Bridging the gap between disruptive discovery products and real-world patient reach, we identify high-potential compounds and technologies for in-licensing, clinically demonstrate their safety and efficacy and then select large pharmaceutical commercialization partners to maximize patient access globally.

On March 5, 2020 Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) reported that, since January 1, 2020, it has received proceeds of approximately $5.9 million as a result of the exercise of approximately 26.2 million previously issued Class B common share purchase warrants (the "Class B Warrants") (Press release, Titan Pharmaceuticals, MAR 5, 2020, View Source [SID1234555246]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Class B Warrants were issued in connection with the Company’s public offering completed in October 2019. The Class B Warrants have an exercise price of $0.225 and are set to expire in October 2024. Approximately 14.1 Class B Warrants remain outstanding.

Sunil Bhonsle, Titan’s President and CEO, commented, "We have been very pleased to see this level of warrant exercises and believe that the proceeds received year-to-date will extend our cash runway into the fourth quarter as we continue to drive our commercial activities."